127 related articles for article (PubMed ID: 23884781)
21. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma.
de Groot JW; Zonnenberg BA; van Ufford-Mannesse PQ; de Vries MM; Links TP; Lips CJ; Voest EE
J Clin Endocrinol Metab; 2007 Sep; 92(9):3466-9. PubMed ID: 17579194
[TBL] [Abstract][Full Text] [Related]
22. Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors.
Palazzo M; Lombard-Bohas C; Cadiot G; Matysiak-Budnik T; Rebours V; Vullierme MP; Couvelard A; Hentic O; Ruszniewski P
Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):232-8. PubMed ID: 23108416
[TBL] [Abstract][Full Text] [Related]
23. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg).
Baldelli R; Colao A; Razzore P; Jaffrain-Rea ML; Marzullo P; Ciccarelli E; Ferretti E; Ferone D; Gaia D; Camanni F; Lombardi G; Tamburrano G
J Clin Endocrinol Metab; 2000 Nov; 85(11):4099-103. PubMed ID: 11095439
[TBL] [Abstract][Full Text] [Related]
24. Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.
Petrangolini G; Cuccuru G; Lanzi C; Tortoreto M; Belluco S; Pratesi G; Cassinelli G; Zunino F
Biochem Pharmacol; 2006 Aug; 72(4):405-14. PubMed ID: 16756963
[TBL] [Abstract][Full Text] [Related]
25. Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro.
Ferrari SM; Fallahi P; La Motta C; Bocci G; Corrado A; Materazzi G; Galleri D; Piaggi S; Danesi R; Da Settimo F; Miccoli P; Antonelli A
Surgery; 2014 Nov; 156(5):1167-76. PubMed ID: 25151558
[TBL] [Abstract][Full Text] [Related]
26. Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer.
Sun Y; Du F; Gao M; Ji Q; Li Z; Zhang Y; Guo Z; Wang J; Chen X; Wang J; Chi Y; Tang P
Thyroid; 2018 Nov; 28(11):1455-1461. PubMed ID: 30142994
[TBL] [Abstract][Full Text] [Related]
27. Update on medullary thyroid cancer.
Hu MI; Ying AK; Jimenez C
Endocrinol Metab Clin North Am; 2014 Jun; 43(2):423-42. PubMed ID: 24891170
[TBL] [Abstract][Full Text] [Related]
28. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
[TBL] [Abstract][Full Text] [Related]
29. Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase.
Tomoda C; Moatamed F; Naeim F; Hershman JM; Sugawara M
Exp Biol Med (Maywood); 2008 Nov; 233(11):1433-40. PubMed ID: 18791128
[TBL] [Abstract][Full Text] [Related]
30. Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results.
Raderer M; Hamilton G; Kurtaran A; Valencak J; Haberl I; Hoffmann O; Kornek GV; Vorbeck F; Hejna MH; Virgolini I; Scheithauer W
Br J Cancer; 1999 Feb; 79(3-4):535-7. PubMed ID: 10027326
[TBL] [Abstract][Full Text] [Related]
31. Synthesis, conformational analysis and bioactivity of Lan-7, a lanthionine analog of TT-232.
Li H; Jiang X; Howell SB; Goodman M
J Pept Sci; 2000 Jan; 6(1):26-35. PubMed ID: 10674717
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days.
Bronstein M; Musolino N; Jallad R; Cendros JM; Ramis J; Obach R; Leselbaum A; Catus F
Clin Endocrinol (Oxf); 2005 Nov; 63(5):514-9. PubMed ID: 16268802
[TBL] [Abstract][Full Text] [Related]
33. Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer.
Strock CJ; Park JI; Rosen DM; Ruggeri B; Denmeade SR; Ball DW; Nelkin BD
J Clin Endocrinol Metab; 2006 Jan; 91(1):79-84. PubMed ID: 16263812
[TBL] [Abstract][Full Text] [Related]
34. Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models.
Broutin S; Ameur N; Lacroix L; Robert T; Petit B; Oumata N; Talbot M; Caillou B; Schlumberger M; Dupuy C; Bidart JM
Clin Cancer Res; 2011 Apr; 17(7):2044-54. PubMed ID: 21325074
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
Giusti M; Gussoni G; Cuttica CM; Giordano G
J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
[TBL] [Abstract][Full Text] [Related]
36. Anti-tumoral effect of a celecoxib low dose on a model of human medullary thyroid cancer in nude mice.
Quidville V; Segond N; Tebbi A; Cohen R; Jullienne A; Lepoivre M; Lausson S
Thyroid; 2009 Jun; 19(6):613-21. PubMed ID: 19281427
[TBL] [Abstract][Full Text] [Related]
37. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients.
Koutsilieris M; Mitsiades C; Dimopoulos T; Ioannidis A; Ntounis A; Lambou T
J Clin Endocrinol Metab; 2001 Dec; 86(12):5729-36. PubMed ID: 11739429
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide.
Kuhn JM; Arlot S; Lefebvre H; Caron P; Cortet-Rudelli C; Archambaud F; Chanson P; Tabarin A; Goth MI; Blumberg J; Catus F; Ispas S; Beck-Peccoz P
J Clin Endocrinol Metab; 2000 Apr; 85(4):1487-91. PubMed ID: 10770186
[TBL] [Abstract][Full Text] [Related]
39. The therapeutic value of SST-A octreotide alone or with adjuvant treatment in patients with advanced medullary thyroid carcinoma and positive (111)In-octreotide scan.
Vainas I; Drimonitis A; Boudina M; Kaprara A; Iakovou I; Salem N; Koussis C
Hell J Nucl Med; 2005; 8(1):43-7. PubMed ID: 15886753
[TBL] [Abstract][Full Text] [Related]
40. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine.
Wu LT; Averbuch SD; Ball DW; de Bustros A; Baylin SB; McGuire WP
Cancer; 1994 Jan; 73(2):432-6. PubMed ID: 8293411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
